Cytochrome B5 type A alleviates HCC metastasis via regulating STOML2 related autophagy and promoting sensitivity to ruxolitinib

作者：Hongrui Guo, Shuhang Liang, Yan Wang, Shuo Zhou, Dalong Yin, Shugeng Zhang, Jizhou Wang, Jizhou Wang, Dehai Wu, Kun Ma, Yufeng Liu, Yufeng Liu, Linmao Sun, Changyong Ji, Xianying Li, Huanran Zhou, Guangchao Yang, Xinyu Guo, Tianming Cui, Zihao Li, Lianxin Liu, Yao Liu, Jiabei Wang, Jiabei Wang, Lianxin Liu · 发表于：Cell Death and Disease · 年份：2022 · DOI：10.1038/s41419-022-05053-8 · 被引用次数：25 · 研究领域：Protein Tyrosine Phosphatases、Galectins and Cancer Biology、RNA modifications and cancer

The incidence of hepatocellular carcinoma (HCC) is increasing in the world. However, its role and underlying molecular mechanism in HCC progression remain unclear. We found that CYB5A plays a key role in HCC metastasis by inhibiting the JAK1/STAT3 pathway through binding to STOML2. CYB5A combined with STOML2 can predict the outcome of patients. To demonstrate the effect of CYB5A on JAK1 inhibitor function, we applied Ruxolitinib in metastatic tumors with high CYB5A expression and found that it slowed disease progression and prolonged survival in mice. To the best of our knowledge, this study is the first to report the Ruxolitinib effect on the metastatic ability of HCC cells in vivo and in vitro.